logo

Last Update

This profile was last updated on 8/15/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong John Kolman?

John L. Kolman

Executive Director and Head of Translational Medicine

QPS Holdings LLC

HQ Phone:  (302) 369-5601

Direct Phone: (302) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

QPS Holdings LLC

3 Innovation Way Ste 240

Newark, Delaware,19711

United States

Company Description

Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) and life sciences products supplier supporting discovery, preclinical, and clinical drug development, providing quality services to pharmaceutical and biotechnology clients worldw...more

Background Information

Employment History

Senior Administrator

Plexus Corp.


Executive Director

BioReliance Corporation


Senior Scientist

Invitrogen Corporation


Post Doc and Staff Scientist

Salk Institute


Senior Director, Research and Development

BioCoR Research


Web References(31 Total References)


QPS Announces John Kolman as Executive Director and Head of Translational Medicine

www.qps.com [cached]

QPS Announces John Kolman as Executive Director and Head of Translational Medicine
(Newark, DE; November 24, 2014) - QPS Holdings, LLC, a leading full-service contract research organization, has named John Kolman, M.Phil., Ph.D. as Executive Director and Head of Translational Medicine. John Kolman will work with QPS' Strategic Leadership Team to assist clients in quickly moving their drug candidates from pre-clinical through late stage development by employing diagnostic testing that allows the selection of appropriate and optimal drug therapies based on a patient's DNA, RNA, and/or protein pathophysiology. "After many years of successful leadership by LingSing Chen, who recently retired after serving as Vice President and Global Head of Translational Medicine and Biosimilars, it is my pleasure to announce the hiring of John Kolman as her successor," said Ben Chien, PhD, QPS President and CEO. "In his new position, John will be heading up our translational medicine division while serving our clients as an expert in biomarker research & development. As an effective business executive and innovative life scientist whose broad expertise includes all areas pertinent to translational and individualized medicine, John will be a major asset in this exciting and extremely important role, so crucial to our future success in helping clients develop personalized drug therapies." Kolman comes to QPS after over 20 years in the pharmaceutical R&D industry, having held multiple leadership roles. He is also well known throughout the industry for his scientific leadership, as evidenced by recent speaking engagements at fora such as the World PGx (Pharmacogenomics) Summit (San Francisco), the International Conference on Biomarkers and Clinical Research (Philadelphia), and the PDA/FDA (Parenteral Drug Association/Food and Drug Administration) Advanced Technologies for Virus Detection in Biologicals Conference (Bethesda). Kolman received his Ph.D. in Molecular Biophysics and Biochemistry from Yale University and his published works have appeared in such noteworthy periodicals as Science and Biologicals, and are pending with Applied Microbiology and Biotechnology, the Journal of Pharmaceutical Science and Technology, BioProcessing Journal, and in the PDA Press. His experience in biomarkers, biologics, pharmacogenomics, genetics, and bioinformatics has earned him recognition as an expert in these fields.


QPS - CRO for translational medicine services & biomarker method development

www.qps.com [cached]

John L Kolman
John L Kolman Executive Director and Head of Translational Medicine John L Kolman John L Kolman, Ph.D. Executive Director and Head of Translational Medicine John joined QPS, LLC in 2014 to lead the Translational Medicine unit. He has twenty years' experience designing assays and supporting clinical trial testing in regulated laboratory environments. Previous leadership roles include Head of Genomics for BioReliance Inc., as well as the Corporate Research Lab of Invitrogen (Thermo Fisher Scientific). He is experienced with molecular and immunological test systems and specializes in pharmacogenomics studies. He has an extensive publication record, makes public speaking appearances and supports client submissions to the FDA. Dr. Kolman received his Ph.D. in molecular Biophysics and Biochemistry from Yale University, specializing in molecular virology and is an alumnus of the University of Illinois.


QPS is dedicated to quality, accuracy accountability and total compliance

www.qps.com [cached]

We kindly invite you to put our biosimilar development experience to the test by getting in touch with John Kolman (john.kolman@qps.com) who heads up the multidisciplinary Global Biosimilar Team at QPS.


www.fiercebiotech.com

John Kolman, executive director and head of translational medicine at QPS, added: "As a full CRO, we must meet the needs of the large pharmaceutical and biopharmaceutical industry in a productive manner with solutions that offer robustness and confidence.


SCIEX and QPS Holdings Enter Collaboration to Establish the BioBA Solution for Bioanalysis of Biologics

www.qps.com [cached]

"As a full CRO, we must meet the needs of the large pharmaceutical and biopharmaceutical industry in a productive manner with solutions that offer robustness and confidence," said John Kolman, Executive Director and Head of Translational Medicine at QPS.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory